Shots:
- The P-III (evERA Breast Cancer) trial evaluated giredestrant + everolimus vs SoC ET + everolimus in ER+, HER2-, LA/M breast cancer pts previously treated with CDK4/6 inhibitors & endocrine therapy (ET) in adj. or LA/M settings
- Trial met its co-1EPs of improved PFS in both the ITT & ESR1-mutated populations, while OS showed a favorable trend & will be further analyzed; data to be shared with global health authorities
- Giredestrant is being evaluated across various settings & treatment lines for breast cancer incl. P-III (lidERA Breast Cancer) trial (with SoC ET), P-III (persevERA Breast Cancer) trial (with palbociclib), P-III (pionERA Breast Cancer) trial (with CDK 4/6 inhibitor) & P-III (heredERA Breast Cancer) trial (with Phesgo)
Ref: Roche | Image: Roche| Press Release
Related News:- Roche Reports the European CE Mark Approval of Contivue to Treat Neovascular Age-Related Macular Degeneration
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
